{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:30:57Z","timestamp":1790173857194,"version":"4.1.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"German Jose Carreras Leukemia Foundation","award":["R12\/08"],"award-info":[{"award-number":["R12\/08"]}]},{"name":"Margarete Clemens Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13045-017-0533-9","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T12:42:19Z","timestamp":1508244139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The role of B cell antigen receptors in mantle cell lymphoma"],"prefix":"10.1186","volume":"10","author":[{"given":"Michael","family":"Fichtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3358-6568","authenticated-orcid":false,"given":"Martin","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"533_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","volume":"20","author":"CA Janeway","year":"2002","unstructured":"Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197\u2013216.","journal-title":"Annu Rev Immunol"},{"key":"533_CR2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cell.2006.02.001","volume":"124","author":"MD Cooper","year":"2006","unstructured":"Cooper MD, Alder MN. The evolution of adaptive immune systems. Cell. 2006;124:815\u201322.","journal-title":"Cell"},{"key":"533_CR3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/302575a0","volume":"302","author":"S Tonegawa","year":"1983","unstructured":"Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302:575\u201381.","journal-title":"Nature"},{"key":"533_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","volume":"5","author":"R K\u00fcppers","year":"2005","unstructured":"K\u00fcppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251\u201362.","journal-title":"Nat Rev Cancer"},{"key":"533_CR5","unstructured":"Haematological Malignancy Research Network (HMRN). 2017.\u00a0 https:\/\/www.hmrn.org\/statistics\/incidence . Accessed 12 Oct 2017."},{"key":"533_CR6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277\u2013300.","journal-title":"CA Cancer J Clin"},{"key":"533_CR7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"533_CR8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2010.33.3252","volume":"29","author":"H Nogai","year":"2011","unstructured":"Nogai H, D\u00f6rken B, Lenz G. Pathogenesis of non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2011;29:1803\u201311.","journal-title":"J Clin Oncol"},{"key":"533_CR9","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin\u2019s lymphoma. Blood. 1997;89:3909\u201318.","journal-title":"Blood"},{"key":"533_CR10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","volume":"90","author":"JM Vose","year":"2015","unstructured":"Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management: mantle cell lymphoma. Am J Hematol. 2015;90:739\u201345.","journal-title":"Am J Hematol"},{"key":"533_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL network. Br J Haematol. 2005;131:29\u201338.","journal-title":"Br J Haematol"},{"key":"533_CR12","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62\u201371.","journal-title":"Ann Oncol"},{"key":"533_CR13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, R\u00e4ty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355\u201362.","journal-title":"Br J Haematol"},{"key":"533_CR14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet Lond. Engl. 2016;388:565\u201375.","journal-title":"Lancet Lond. Engl."},{"key":"533_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","volume":"39","author":"JE Romaguera","year":"2000","unstructured":"Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk. Lymphoma. 2000;39:77\u201385.","journal-title":"Leuk. Lymphoma."},{"key":"533_CR16","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"533_CR17","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250\u201360.","journal-title":"N Engl J Med"},{"key":"533_CR18","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2352-3026(16)30187-9","volume":"4","author":"A Lipsky","year":"2017","unstructured":"Lipsky A, Martin P. Bendamustine-rituximab in mantle cell lymphoma. Lancet Haematol. 2017;4:e2\u20133.","journal-title":"Lancet Haematol"},{"key":"533_CR19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/10428190903026518","volume":"50","author":"CS Tam","year":"2009","unstructured":"Tam CS, Khouri IF. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma. Leuk. Lymphoma. 2009;50:1239\u201348.","journal-title":"Leuk. Lymphoma."},{"key":"533_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.iy.10.040192.000525","volume":"10","author":"M Reth","year":"1992","unstructured":"Reth M. Antigen receptors on B lymphocytes. Annu Rev Immunol. 1992;10:97\u2013121.","journal-title":"Annu Rev Immunol"},{"key":"533_CR21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/343760a0","volume":"343","author":"J Hombach","year":"1990","unstructured":"Hombach J, Tsubata T, Leclercq L, Stappert H, Reth M. Molecular components of the B-cell antigen receptor complex of the IgM class. Nature. 1990;343:760\u20132.","journal-title":"Nature"},{"key":"533_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/j.1460-2075.1994.tb06237.x","volume":"13","author":"H Flaswinkel","year":"1994","unstructured":"Flaswinkel H, Reth M. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J. 1994;13:83\u20139.","journal-title":"EMBO J"},{"key":"533_CR23","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","volume":"125","author":"HW Schroeder","year":"2010","unstructured":"Schroeder HW, Cavacini L. Structure and function of Immunoglobulins. J Allergy Clin Immunol. 2010;125:S41\u201352.","journal-title":"J Allergy Clin Immunol"},{"key":"533_CR24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.iy.01.040183.002435","volume":"1","author":"T Honjo","year":"1983","unstructured":"Honjo T. Immunoglobulin genes. Annu Rev Immunol. 1983;1:499\u2013528.","journal-title":"Annu Rev Immunol"},{"key":"533_CR25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1128\/MCB.06138-11","volume":"32","author":"A Tinguely","year":"2012","unstructured":"Tinguely A, Chemin G, P\u00e9ron S, Sirac C, Reynaud S, Cogn\u00e9 M, et al. Cross talk between immunoglobulin heavy-chain transcription and RNA surveillance during B cell development. Mol Cell Biol. 2012;32:107\u201317.","journal-title":"Mol Cell Biol"},{"key":"533_CR26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/381751a0","volume":"381","author":"K Rajewsky","year":"1996","unstructured":"Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381:751\u20138.","journal-title":"Nature"},{"key":"533_CR27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.smim.2012.05.002","volume":"24","author":"H Saribasak","year":"2012","unstructured":"Saribasak H, Gearhart PJ. Does DNA repair occur during somatic hypermutation? Semin Immunol. 2012;24:287\u201392.","journal-title":"Semin Immunol"},{"key":"533_CR28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-319-13150-4_2","volume":"165","author":"SL Ondrejka","year":"2015","unstructured":"Ondrejka SL, Hsi ED. Pathology of B-cell lymphomas: diagnosis and biomarker discovery. Cancer Treat Res. 2015;165:27\u201350.","journal-title":"Cancer Treat Res"},{"key":"533_CR29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V89.3.965","volume":"89","author":"K Uchimaru","year":"1997","unstructured":"Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T, et al. Detection of Cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11; 14)(q13; q32)-bearing B-cell malignancies and\/or mantle cell lymphoma. Blood. 1997;89:965\u201374.","journal-title":"Blood"},{"key":"533_CR30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MOH.0000000000000057","volume":"21","author":"N Saba","year":"2014","unstructured":"Saba N, Wiestner A. Do mantle cell lymphomas have an \u201cAchilles heel\u201d? Curr Opin Hematol. 2014;21:350\u20137.","journal-title":"Curr Opin Hematol"},{"key":"533_CR31","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","volume":"25","author":"I Salaverria","year":"2007","unstructured":"Salaverria I, Zettl A, Be\u00e0 S, Moreno V, Valls J, Hartmann E, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:1216\u201322.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"533_CR32","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood-2013-01-475954","volume":"121","author":"M Seto","year":"2013","unstructured":"Seto M. Cyclin D1-negative mantle cell lymphoma. Blood. 2013;121:1249\u201350.","journal-title":"Blood"},{"key":"533_CR33","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","volume":"106","author":"K Fu","year":"2005","unstructured":"Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315\u201321.","journal-title":"Blood"},{"key":"533_CR34","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","volume":"121","author":"I Salaverria","year":"2013","unstructured":"Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(\u2212) mantle cell lymphoma. Blood. 2013;121:1394\u2013402.","journal-title":"Blood"},{"key":"533_CR35","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood-2007-10-120824","volume":"111","author":"C Herens","year":"2008","unstructured":"Herens C, Lambert F, Quintanilla-Martinez L, Bisig B, Deusings C, de Leval L. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood. 2008;111:1745\u20136.","journal-title":"Blood"},{"key":"533_CR36","doi-asserted-by":"crossref","unstructured":"D\u00f6lken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2\/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. . J. Clin. Oncol. Off. J. Am. Soc. Clin Oncologia 1996;14:1333\u20131344.","DOI":"10.1200\/JCO.1996.14.4.1333"},{"key":"533_CR37","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.V85.9.2528.bloodjournal8592528","volume":"85","author":"J Limpens","year":"1995","unstructured":"Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood. 1995;85:2528\u201336.","journal-title":"Blood"},{"key":"533_CR38","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416\u201323.","journal-title":"J Clin Invest"},{"key":"533_CR39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"533_CR40","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor \u03baB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861\u201374.","journal-title":"J Exp Med"},{"key":"533_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young R, Romesser PB, et al. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature. 2010;463:88\u201392.","journal-title":"Nature"},{"key":"533_CR42","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417\u201329.","journal-title":"N Engl J Med"},{"key":"533_CR43","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848\u201354.","journal-title":"Blood"},{"key":"533_CR44","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","volume":"119","author":"A Agathangelidis","year":"2012","unstructured":"Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan X-J, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012;119:4467\u201375.","journal-title":"Blood"},{"key":"533_CR45","doi-asserted-by":"crossref","first-page":"e1e5992","DOI":"10.1371\/journal.pone.0015992","volume":"5","author":"M Binder","year":"2010","unstructured":"Binder M, L\u00e9chenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, et al. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS One. 2010;5:e1e5992.","journal-title":"PLoS One"},{"key":"533_CR46","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","volume":"118","author":"A Hadzidimitriou","year":"2011","unstructured":"Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue M-H, Pedersen LB, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118:3088\u201395.","journal-title":"Blood"},{"key":"533_CR47","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2119\/2008-00102.Catera","volume":"14","author":"R Catera","year":"2008","unstructured":"Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med Camb Mass. 2008;14:665\u201374.","journal-title":"Mol Med Camb Mass"},{"key":"533_CR48","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1172\/JCI24387","volume":"115","author":"M Herv\u00e9","year":"2005","unstructured":"Herv\u00e9 M, Xu K, Ng Y-S, Wardemann H, Albesiano E, Messmer BT, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest. 2005;115:1636\u201343.","journal-title":"J Clin Invest"},{"key":"533_CR49","first-page":"4887","volume":"190","author":"S-C Cha","year":"2013","unstructured":"Cha S-C, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, et al. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol Baltim Md 1950. 2013;190:4887\u201398.","journal-title":"J Immunol Baltim Md 1950"},{"key":"533_CR50","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood-2009-09-244251","volume":"115","author":"CC Chu","year":"2010","unstructured":"Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115:3907\u201315.","journal-title":"Blood"},{"key":"533_CR51","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2007-11-125450","volume":"111","author":"AL Myhrinder","year":"2008","unstructured":"Myhrinder AL, Hellqvist E, Sidorova E, S\u00f6derberg A, Baxendale H, Dahle C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111:3838\u201348.","journal-title":"Blood"},{"key":"533_CR52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","volume":"489","author":"MD Minden","year":"2012","unstructured":"Minden MD, \u00dcbelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489:309\u201312.","journal-title":"Nature"},{"key":"533_CR53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2012-09-454439","volume":"121","author":"M Binder","year":"2013","unstructured":"Binder M, M\u00fcller F, Frick M, Wehr C, Simon F, Leistler B, et al. CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood. 2013;121:239\u201341.","journal-title":"Blood"},{"key":"533_CR54","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","volume":"123","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123:2988\u201396.","journal-title":"Blood"},{"key":"533_CR55","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","volume":"99","author":"D Zhu","year":"2002","unstructured":"Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood. 2002;99:2562\u20138.","journal-title":"Blood"},{"key":"533_CR56","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1074\/jbc.M602690200","volume":"282","author":"CM Radcliffe","year":"2007","unstructured":"Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem. 2007;282:7405\u201315.","journal-title":"J Biol Chem"},{"key":"533_CR57","doi-asserted-by":"crossref","first-page":"18587","DOI":"10.1073\/pnas.1009388107","volume":"107","author":"V Coelho","year":"2010","unstructured":"Coelho V, Krysov S, Ghaemmaghami AM, Emara M, Potter KN, Johnson P, et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci U S A. 2010;107:18587\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"533_CR58","doi-asserted-by":"crossref","first-page":"E2567","DOI":"10.1073\/pnas.1406974111","volume":"111","author":"Z Sabouri","year":"2014","unstructured":"Sabouri Z, Schofield P, Horikawa K, Spierings E, Kipling D, Randall KL, et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc Natl Acad Sci U S A. 2014;111:E2567\u201375.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"533_CR59","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2014-11-609404","volume":"125","author":"D Schneider","year":"2015","unstructured":"Schneider D, D\u00fchren-von Minden M, Alkhatib A, Setz C, van Bergen CAM, Benki\u00dfer-Petersen M, et al. Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. Blood. 2015;125:3287\u201396.","journal-title":"Blood"},{"key":"533_CR60","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2141.2009.07849.x","volume":"147","author":"LA Anderson","year":"2009","unstructured":"Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol. 2009;147:444\u20139.","journal-title":"Br J Haematol"},{"key":"533_CR61","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1365-2141.2007.06859.x","volume":"139","author":"O Landgren","year":"2007","unstructured":"Landgren O, Gridley G, Check D, Caporaso NE, Morris BL. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol. 2007;139:791\u20138.","journal-title":"Br J Haematol"},{"key":"533_CR62","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2006-08-044008","volume":"109","author":"O Landgren","year":"2007","unstructured":"Landgren O, Rapkin JS, Caporaso NE, Mellemkjaer L, Gridley G, Goldin LR, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood. 2007;109:2198\u2013201.","journal-title":"Blood"},{"key":"533_CR63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13402-011-0019-7","volume":"34","author":"C Pighi","year":"2011","unstructured":"Pighi C, Gu T-L, Dalai I, Barbi S, Parolini C, Bertolaso A, et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol Dordr. 2011;34:141\u201353.","journal-title":"Cell Oncol Dordr"},{"key":"533_CR64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba NS, Liu D, Herman SEM, Underbayev C, Tian X, Behrend D, et al. Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma. Blood. 2016;128:82\u201392.","journal-title":"Blood"},{"key":"533_CR65","doi-asserted-by":"publisher","unstructured":"Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L. Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med. 2017. doi: 10.1111\/joim.12600","DOI":"10.1111\/joim.12600"},{"key":"533_CR66","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S, Pham TH-T, Fend F, Jaffe ES, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006;108:1668\u201376.","journal-title":"Blood"},{"key":"533_CR67","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","volume":"129","author":"JH Myklebust","year":"2017","unstructured":"Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, W\u00e4lchli S, et al. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood. 2017;129:759\u201370.","journal-title":"Blood"},{"key":"533_CR68","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","volume":"39","author":"F Bertoni","year":"2007","unstructured":"Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol. 2007;39:1747\u201353.","journal-title":"Int J Biochem Cell Biol"},{"key":"533_CR69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/10428199909145958","volume":"36","author":"F Bertoni","year":"1999","unstructured":"Bertoni F, Zucca E, Genini D, Cazzaniga G, Roggero E, Ghielmini M, et al. Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. Leuk Lymphoma. 1999;36:147\u201350.","journal-title":"Leuk Lymphoma"},{"key":"533_CR70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2008.199","volume":"22","author":"M Schraders","year":"2009","unstructured":"Schraders M, Oeschger S, Kluin PM, Hebeda K, Schuuring E, Groenen PJTA, et al. Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. Mod Pathol. 2009;22:416\u201325.","journal-title":"Mod Pathol"},{"key":"533_CR71","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2002-11-3479","volume":"101","author":"SH Walsh","year":"2003","unstructured":"Walsh SH, Thors\u00e9lius M, Johnson A, S\u00f6derberg O, Jerkeman M, Bj\u00f6rck E, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood. 2003;101:4047\u201354.","journal-title":"Blood"},{"key":"533_CR72","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307\u201316.","journal-title":"Cancer Res"},{"key":"533_CR73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0609.2002.01662.x","volume":"68","author":"M Thors\u00e9lius","year":"2002","unstructured":"Thors\u00e9lius M, Walsh S, Eriksson I, Thunberg U, Johnson A, Backlin C, et al. Somatic hypermutation and VH gene usage in mantle cell lymphoma. Eur J Haematol. 2002;68:217\u201324.","journal-title":"Eur J Haematol"},{"key":"533_CR74","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2002-11-3456","volume":"101","author":"FI Camacho","year":"2003","unstructured":"Camacho FI, Algara P, Rodr\u0131\u0301guez A, Ru\u0131\u0301z-Ballesteros E, Mollejo M, Mart\u0131\u0301nez N, et al. Molecular heterogeneity in MCL defined by the use of specificV H genes and the frequency of somatic mutations. Blood. 2003;101:4042\u20136.","journal-title":"Blood"},{"key":"533_CR75","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840\u20137.","journal-title":"Blood"},{"key":"533_CR76","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.3324\/haematol.2016.141929","volume":"101","author":"M Fichtner","year":"2016","unstructured":"Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gosch B, et al. Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. Haematologica. 2016;101:e378\u201381.","journal-title":"Haematologica"},{"key":"533_CR77","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/leu.2014.209","volume":"29","author":"M Loeffler","year":"2015","unstructured":"Loeffler M, Kreuz M, Haake A, Hasenclever D, Trautmann H, Arnold C, et al. Genomic and epigenomic co-evolution in follicular lymphomas. Leukemia. 2015;29:456\u201363.","journal-title":"Leukemia"},{"key":"533_CR78","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","volume":"301","author":"H Wardemann","year":"2003","unstructured":"Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374\u20137.","journal-title":"Science"},{"key":"533_CR79","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ajpath.2015.02.006","volume":"185","author":"A Xochelli","year":"2015","unstructured":"Xochelli A, Sutton L-A, Agathangelidis A, Stalika E, Karypidou M, Marantidou F, et al. Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. Am J Pathol. 2015;185:1740\u20138.","journal-title":"Am J Pathol"},{"issue":"7","key":"533_CR80","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ajpath.2017.02.017","volume":"187","author":"E Pouliou","year":"2017","unstructured":"Pouliou E, Xochelli A, Kanellis G, Stalika E, Sutton L-A, Navarro A, et al. Numerous ontogenetic roads to mantle cell lymphoma: Immunogenetic and Immunohistochemical evidence. Am J Pathol. 2017;187(7):1454\u20138.","journal-title":"Am J Pathol"},{"key":"533_CR81","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1128\/MMBR.60.3.473-482.1996","volume":"60","author":"BT Huber","year":"1996","unstructured":"Huber BT, Hsu PN, Sutkowski N. Virus-encoded superantigens. Microbiol Rev. 1996;60:473\u201382.","journal-title":"Microbiol Rev"},{"key":"533_CR82","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri1853","volume":"6","author":"GJ Silverman","year":"2006","unstructured":"Silverman GJ, Goodyear CS. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat. Rev. Immunol. 2006;6:465\u201375.","journal-title":"Nat. Rev. Immunol."},{"key":"533_CR83","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1073\/pnas.97.10.5399","volume":"97","author":"M Graille","year":"2000","unstructured":"Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB, et al. Crystal structure of a Staphylococcus aureus protein a domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A. 2000;97:5399\u2013404.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"533_CR84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0959-440X(95)80031-X","volume":"5","author":"M Tashiro","year":"1995","unstructured":"Tashiro M, Montelione GT. Structures of bacterial immunoglobulin-binding domains and their complexes with immunoglobulins. Curr Opin Struct Biol. 1995;5:471\u201381.","journal-title":"Curr Opin Struct Biol"},{"key":"533_CR85","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","volume":"339","author":"FD Lowy","year":"1998","unstructured":"Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520\u201332.","journal-title":"N Engl J Med"},{"key":"533_CR86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.meegid.2008.09.012","volume":"9","author":"A van Belkum","year":"2009","unstructured":"van Belkum A, Melles DC, Nouwen J, van Leeuwen WB, van Wamel W, Vos MC, et al. Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus. Infect Genet Evol. 2009;9:32\u201347.","journal-title":"Infect Genet Evol"},{"key":"533_CR87","first-page":"2974","volume":"153","author":"SV Kristiansen","year":"1994","unstructured":"Kristiansen SV, Pascual V, Lipsky PE. Staphylococcal protein A induces biased production of Ig by VH3-expressing B lymphocytes. J. Immunol. Baltim. Md 1950. 1994;153:2974\u201382.","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"533_CR88","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.leukres.2014.01.001","volume":"38","author":"MJ Baptista","year":"2014","unstructured":"Baptista MJ, Calpe E, Fernandez E, Colomo L, Cardesa-Salzmann TM, Abrisqueta P, et al. Analysis of the IGHV region in Burkitt\u2019s lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. Leuk Res. 2014;38:509\u201315.","journal-title":"Leuk Res"},{"key":"533_CR89","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2007-07-099564","volume":"111","author":"F Murray","year":"2008","unstructured":"Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111:1524\u201333.","journal-title":"Blood"},{"key":"533_CR90","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20020552","volume":"197","author":"CS Goodyear","year":"2003","unstructured":"Goodyear CS, Silverman GJ. Death by a B cell superantigen: in vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin. J Exp Med. 2003;197:1125\u201339.","journal-title":"J Exp Med"},{"key":"533_CR91","first-page":"679","volume":"9","author":"M Graille","year":"2001","unstructured":"Graille M, Stura EA, Housden NG, Beckingham JA, Bottomley SP, Beale D, et al. Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Struct Lond Engl 1993. 2001;9:679\u201387.","journal-title":"Struct Lond Engl 1993"},{"key":"533_CR92","doi-asserted-by":"crossref","unstructured":"Potter KN, Hobby P, Klijn S, Stevenson FK, Sutton BJ. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen. J Immunol. 2002;169:3777\u201382.","DOI":"10.4049\/jimmunol.169.7.3777"},{"key":"533_CR93","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin9s lymphoma. Blood. 1997;90:2188\u201395.","journal-title":"Blood"},{"key":"533_CR94","first-page":"148","volume":"35","author":"E Dotan","year":"2010","unstructured":"Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma. Pharm Ther. 2010;35:148\u201357.","journal-title":"Pharm Ther"},{"key":"533_CR95","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, W\u00f6rmann B, D\u00fchrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:1984\u201392.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"533_CR96","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"533_CR97","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922\u20136.","journal-title":"Nat Med"},{"key":"533_CR98","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A M\u00f3csai","year":"2010","unstructured":"M\u00f3csai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10:387\u2013402.","journal-title":"Nat Rev Immunol"},{"key":"533_CR99","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","volume":"132","author":"A Rinaldi","year":"2006","unstructured":"Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303\u201316.","journal-title":"Br J Haematol"},{"key":"533_CR100","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578\u201385.","journal-title":"Blood"},{"issue":"4","key":"533_CR101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MOH.0000000000000048","volume":"21","author":"M Buchner","year":"2014","unstructured":"Buchner M, M\u00fcschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014;21(4):341\u20139.","journal-title":"Curr Opin Hematol"},{"key":"533_CR102","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37:1271\u20137.","journal-title":"Leuk Res"},{"key":"533_CR103","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287\u201396.","journal-title":"Blood"},{"key":"533_CR104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li S-J, Schultz BE, Sprengeler PA, Burrill LC, et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem. 2007;2:58\u201361.","journal-title":"ChemMedChem"},{"key":"533_CR105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"533_CR106","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219\u201332.","journal-title":"Nat Rev Cancer"},{"key":"533_CR107","doi-asserted-by":"crossref","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J. Clin. Oncol. Off. J. Am. Soc. Clin Oncologia 2013;31:88\u201394.","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"533_CR108","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet Lond Engl. 2016;387:770\u20138.","journal-title":"Lancet Lond Engl"},{"key":"533_CR109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chun Chan F, et al. Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87\u201392.","journal-title":"Nat Med"},{"key":"533_CR110","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363.","journal-title":"Blood"},{"key":"533_CR111","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bcmd.2015.06.016","volume":"55","author":"K Bojarczuk","year":"2015","unstructured":"Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, et al. B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells Mol Dis. 2015;55:255\u201365.","journal-title":"Blood Cells Mol Dis"},{"key":"533_CR112","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398\u2013405.","journal-title":"Blood"},{"issue":"9","key":"533_CR113","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(9):2169\u201378.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"533_CR114","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"533_CR115","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, Bernd H-W, Hartmann S, Loddenkemper C, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1386\u201394.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"533_CR116","doi-asserted-by":"crossref","unstructured":"Wu Y-C, Kipling D, Leong HS, Martin V, Ademokun AA, Dunn-Walters DK. High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood. 2010;116:1070\u20138.","DOI":"10.1182\/blood-2010-03-275859"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0533-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:55:48Z","timestamp":1750949748000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0533-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1186\/s13045-017-0533-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]},"article-number":"164"}}